Gail E. Sonenshein
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$4.7MFederal grants as PI10 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
10 awards · $4.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 8, 2023 | NIH | SBIR Phase II Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | $1.0M | ADECTO PHARMACEUTICALS, INC. |
| Aug 17, 2022 | NIH | SBIR Phase II Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | $1.0M | ADECTO PHARMACEUTICALS, INC. |
| Jul 31, 2019 | NIH | SBIR Phase II Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $2K | ADECTO PHARMACEUTICALS, INC. |
| Jul 23, 2019 | NIH | SBIR Phase II Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $1.0M | ADECTO PHARMACEUTICALS, INC. |
| Feb 19, 2019 | NIH | SBIR Phase I Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | $300K | ADECTO PHARMACEUTICALS, INC. |
| Aug 29, 2018 | NIH | SBIR Phase II Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $1.0M | ADECTO PHARMACEUTICALS, INC. |
| May 23, 2018 | NIH | STTR Phase I Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $3K | ADECTO PHARMACEUTICALS, INC. |
| Jan 12, 2017 | NIH | STTR Phase I Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $50K | ADECTO PHARMACEUTICALS, INC. |
| Sep 19, 2016 | NIH | STTR Phase I Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $63K | ADECTO PHARMACEUTICALS, INC. |
| Apr 14, 2016 | NIH | STTR Phase I Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | $300K | ADECTO PHARMACEUTICALS, INC. |
Peer ranks
Federal funding#297
Awards as PI#128
Patents#273
Companies
- ADECTO PHARMACEUTICALS, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.